SCHEMBL924463

SCHEMBL924463

COc1ccc2nc3ccc(O)cc3c(C(=O)Oc3c(C)cc([N+](=O)[O-])cc3C)c2c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PLA2G2A P14555 1/20 0.41
KDM4E B2RXH2 5/20 0.41
HPGD P15428 4/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GRIN2D O15399 1/20 0.40
GRIN2C Q14957 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HSD17B10 Q99714 3/20 0.40
POLB P06746 1/20 0.40
DHODH Q02127 1/20 0.39
LMNA P02545 1/20 0.38
SENP1 Q9P0U3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923930 0.87 PLA2G2A (0.46) MEN1KMT2APLA2G2AKDM4EHPGD
SCHEMBL12943041 0.86 PLA2G2A (0.46) MEN1KMT2APLA2G2AKDM4EHPGD
SCHEMBL12091759 0.84 PLA2G2A (0.48) MEN1KMT2APLA2G2AKDM4EHPGD
SCHEMBL925911 0.82 PLA2G2A (0.42) MEN1KMT2APLA2G2AKDM4EHPGD
SCHEMBL16067319 0.81 CYP3A4 (0.50) MEN1KMT2APLA2G2AKDM4EHPGD
SCHEMBL15355193 0.79 KDM4E (0.50) PLA2G2AKDM4EHPGDALDH1A1MAPT
SCHEMBL7047790 0.79 MAPT (0.55) MEN1KMT2AKDM4EHPGDALDH1A1
SCHEMBL38663303 0.79 PLA2G2A (0.50) MEN1KMT2APLA2G2AKDM4EHPGD
SCHEMBL13104351 0.78 PLA2G2A (0.50) MEN1KMT2APLA2G2AKDM4EHPGD
SCHEMBL3039691 0.77 KDM4E (0.47) MEN1KMT2APLA2G2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1403254-B1 Novel applications of acridinium compounds and derivatives in homogeneous assays SIEMENS HEALTHCARE DIAGNOSTICS (US) 2014-09-17 EP disclosed
EP-1403254-B1 Novel applications of acridinium compounds and derivatives in homogeneous assays SIEMENS HEALTHCARE DIAGNOSTICS (US) 2014-09-17 EP disclosed
US-7875467-B2 Chemiluminescence; quantitative analysis of macromolecules; complexing sample to acridinium compound, labels for improving sensitivity of immunoassays, 2',6'-dimethyl-4'-N-succinimidyloxycaproyl-amidocarbonylphenyl-N10-2,7-tris[O-methoxyhexa(ethylene) glycol-sulfonamidylpropyl]-acridinium-9-carboxylate SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2011-01-25 US disclosed
US-7875467-B2 Chemiluminescence; quantitative analysis of macromolecules; complexing sample to acridinium compound, labels for improving sensitivity of immunoassays, 2',6'-dimethyl-4'-N-succinimidyloxycaproyl-amidocarbonylphenyl-N10-2,7-tris[O-methoxyhexa(ethylene) glycol-sulfonamidylpropyl]-acridinium-9-carboxylate SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2011-01-25 US disclosed
US-7875467-B2 Chemiluminescence; quantitative analysis of macromolecules; complexing sample to acridinium compound, labels for improving sensitivity of immunoassays, 2',6'-dimethyl-4'-N-succinimidyloxycaproyl-amidocarbonylphenyl-N10-2,7-tris[O-methoxyhexa(ethylene) glycol-sulfonamidylpropyl]-acridinium-9-carboxylate SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2011-01-25 US disclosed
US-20090029349-A1 Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) 2009-01-29 US disclosed
US-20090029349-A1 Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) 2009-01-29 US disclosed
US-20090029349-A1 Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) 2009-01-29 US disclosed
US-20080305557-A1 Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) 2008-12-11 US disclosed
US-20080305557-A1 Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) 2008-12-11 US disclosed
US-20080305557-A1 Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) 2008-12-11 US disclosed
US-7319041-B2 Applications of acridinium compounds and derivatives in homogeneous assays SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) 2008-01-15 US disclosed
US-7319041-B2 Applications of acridinium compounds and derivatives in homogeneous assays SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) 2008-01-15 US disclosed
US-7319041-B2 Applications of acridinium compounds and derivatives in homogeneous assays SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) 2008-01-15 US disclosed
US-20040063147-A1 Novel applications of acridinium compounds and derivatives in homogeneous assays BAYER CORPORATION 2004-04-01 US disclosed
EP-1403254-A1 Novel applications of acridinium compounds and derivatives in homogeneous assays Bayer Healthcare, LLC (US) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063147-A1 Novel applications of acridinium compounds and derivatives in homogeneous assays ACR, SSB, NASP MEN1 3019/4885KMT2A 4623/4885PLA2G2A 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.